Drugs / Ibodutant
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01303224 | Oct 2010 → May 2012 | irritable bowel syndrome | Menarini Group | Completed | Met primary |
| Phase 2 | NCT00761007 | Jul 2008 → Feb 2009 | irritable bowel syndrome | Menarini Group | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT02320318 | Oct 2015 → Dec 2016 | irritable bowel syndrome | Menarini Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT02107196 | Mar 2014 → Jun 2015 | irritable bowel syndrome | Menarini Group | Completed | No outcome recorded |
| Phase 3 | NCT02120027 | Feb 2014 → Nov 2015 | irritable bowel syndrome | Menarini Group | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-09-20 | Menarini Group | Results Studio Iris 2 against irritable bowel sindrome menarini.com ↗
The trial has shown to significantly improve symptoms of IBS in about 50% of the treated individuals. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-09-20 | Menarini Group | Studio Iris 2 against irritable bowel sindrome menarini.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ibodutant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02320318 ↗ |
| Known as | Code: MEN 15596 | “Code: MEN 15596” NCT02107196 ↗1“Code: MEN 15596” NCT02120027 ↗ |
| Known as | MEN15596 | “Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Effect of a 4-week Treatment With Oral Doses of Ibodutant (Code: MEN15596) in Irritable Bowel...” NCT00761007 ↗ |
| Action | Inhibit | “ibodutant, a selective neurokinin-2 (NK2) receptor antagonist” PMID 27196574 ↗ Apr 20161“Neurokinin 2 receptor antagonist” CHEMBL266125 ↗ |
| Modality | Small molecule | — CHEMBL266125 ↗ |
| Route | Oral | “through a daily oral administration” NCT00761007 ↗ |
| Target | TACR2 | “Neurokinin 2 receptor antagonist” CHEMBL266125 ↗ |